FDA PreCheck: pilot program, eligibility, timeline

FDA PreCheck is a voluntary program from the US Food and Drug Administration that gives companies building new pharmaceutical manufacturing facilities in the United States earlier and more structured contact with the agency. Instead of meeting FDA mainly at the pre-approval inspection stage, a participant receives feedback on facility design, construction, equipment qualification and quality systems while the site is still being developed.

The FDA PreCheck program is currently running as a pilot. The application window for the first cohort closed on March 1, 2026, and FDA announced seven selected facilities on June 29, 2026. This guide explains how the pilot works, what FDA PreCheck eligibility required, the full FDA PreCheck pilot program 2026 timeline, and what the program does and does not change for drug manufacturers and their supply chains.

What is FDA PreCheck?

FDA PreCheck is an FDA initiative designed to make regulatory review more predictable for new domestic drug manufacturing sites by engaging with the company before any product application is submitted. FDA's FDA PreCheck pilot program page describes it as a voluntary program intended to reduce regulatory barriers for new US pharmaceutical manufacturing facilities. You may also see it written as FDA pre-check or searched as PreCheck FDA, but the agency's own spelling is one word with a capital C.

The program covers facilities that will produce human drugs, biological products or both. It does not cover medical device plants, and it is not a certification or approval for a building. A participating company still needs an approved application before it can market a product made at the new site.

Why FDA created the program

FDA announced PreCheck on August 7, 2025. In its announcement of the FDA PreCheck program, the agency stated that more than half of pharmaceuticals distributed in the US are manufactured overseas and that only 11% of manufacturers producing active pharmaceutical ingredients used in FDA-approved products are US manufacturers. The program was developed in response to Executive Order 14293, signed on May 5, 2025, which directed FDA to streamline review of domestic pharmaceutical manufacturing and to expand programs that give early technical advice before a facility becomes operational.

The practical problem PreCheck addresses is timing. A manufacturer can spend years designing and building a plant, then discover facility-related deficiencies only when an application is under review and an inspection is scheduled. Earlier engagement is meant to surface those issues while design changes are still practical and cheaper to make.

What FDA PreCheck is not

FDA states that participation is not mandatory for product approval and does not guarantee expedited reviews, approvals or inspection outcomes. It does not replace the current good manufacturing practice regulations in 21 CFR parts 210 and 211, or the biologics rules in part 600, which FDA describes as minimum requirements for the methods, facilities and controls used to make drugs. A participant remains responsible for qualification, validation and demonstrating compliance.

How does the FDA PreCheck pilot program work?

The FDA PreCheck pilot program works in two linked phases. In the first, FDA reviews the facility as it is designed and built and the company documents that facility information in a dedicated drug master file. In the second, the company uses that knowledge base when it prepares the first product application that names the new site. FDA's description of the pilot program structure sets out both phases. The table below summarizes what happens in each.

The structure shows that the program mostly shifts facility-related questions earlier. It does not shorten the parts of a review that depend on product data.

Phase 1: facility readiness

The Pre-Operational Review has four elements: design review, pre-construction review, equipment installation and qualification review, and pre-production review. FDA says engagements can happen by teleconference, email or other methods and may include remote assessments or site visits. Later in the review, FDA checks that construction followed the plans it saw earlier. FDA states plainly that the site visit is not an inspection, although it uses its compliance program and investigations manual expectations to judge whether the facility is ready for pre-submission meetings.

Alongside that review, the participant builds a Type V drug master file. FDA's drug master file overview explains that a DMF provides confidential, detailed information about facilities, processes or articles, and that DMFs are neither approved nor disapproved. Under PreCheck, the Type V file acts as a central repository for non-product facility information, such as site operations and quality system design, which can be referenced by future applications. FDA summarizes the idea as "Qualify Once, Reference Many." Unlike routine DMFs, which are reviewed only when an application references them, FDA plans to actively assess these files during the pilot and give feedback. The holder must keep the file current during and after participation.

Phase 2: application submission

Phase 2 starts once the Type V file has sufficient coverage and depth and the Pre-Operational Review engagements are complete. The company then holds pre-submission meetings focused on facility-related chemistry, manufacturing and controls topics before filing the first new drug application, abbreviated new drug application or biologics license application that uses the site. For a new US manufacturer of active pharmaceutical ingredients, FDA may review a Type II DMF before it assesses the application that references it, and the agency recommends raising that early.

FDA's stated aim is to enable earlier inspection timelines in the review cycle because the agency already understands the facility. Later applications from the same participant that use the same site may also benefit from that established knowledge base.

What participants commit to

Selected companies should expect regular FDA engagement through both phases. FDA asks them to allocate adequate resources, provide facility information on time and give access to facility areas during site visits. FDA also reserves the right to decide when a participant graduates from the program.

Who is eligible for FDA PreCheck?

For the initial cohort, a facility had to meet all four FDA PreCheck eligibility requirements listed on FDA's pilot page:

• A new facility. The site could not be an existing facility or an extension of one. It had to have broken ground, plan to break ground by the full proposal deadline, or be in pre-operational development to produce human drugs, biologics or both.

• Located in the United States. The pilot was limited to new facilities in the US and its insular areas.

• Meaningful size. The facility had to produce enough volume to meet a specified market need or contribute significantly to US market supply needs.

• Application and manufacturing commitments. The company had to commit to submitting an original NDA, ANDA or BLA, an application supplement, or a Type II DMF for a small molecule active ingredient during the pilot, and to manufacturing products at the facility for at least three years after approval of products made there under the program.

How FDA prioritized requests

Meeting the requirements did not guarantee a place. FDA asked each submission to meet at least two of six selection priorities. These covered US sourcing of active ingredients, drug products or key starting materials, products that address shortages, critical medicines or supply chain vulnerabilities, a pre-operational development stage with a commitment to the full review, a fast execution plan that quantifies time saved, innovative facility design or construction that could serve as a template, and company experience in pharmaceutical manufacturing. Contract development and manufacturing organizations working with experienced sponsor partners were included in that last priority.

What falls outside the pilot

The first cohort excluded upgrades, extensions and modernization of existing plants. FDA also listed distributed manufacturing and point-of-care systems as out of scope. Each company was limited to one request for a single facility. If your project is a line addition at a current site, the ordinary pathways for application supplements and pre-approval inspections still apply, and you should watch FDA's pages for any change in scope.

What is the FDA PreCheck timeline?

The FDA PreCheck timeline ran from the August 2025 announcement to final cohort selection at the end of June 2026, followed by pre-operational engagements starting in July 2026. FDA published the dates in its PreCheck implementation roadmap on January 21, 2026, after a public meeting and a comment period. The table lists each milestone and its status.

FDA's pilot submission page states that the initial window is closed and that information on future iterations or expansion will be posted there. FDA has not published dates for a second cohort on the pages reviewed for this article, so confirm the current status directly on FDA's program pages before planning around one.

The first cohort of FDA PreCheck manufacturing facilities

FDA received more than 80 requests between February 1 and March 1, 2026. Its June 29, 2026 selection announcement named the seven FDA PreCheck manufacturing facilities below.

The mix of small molecule active ingredients, sterile products, biologics and gene therapies shows that the pilot is not limited to one modality. It does not mean every type of project will qualify in a future round, since FDA said it will keep evaluating the pilot before deciding on future program development.

What does FDA PreCheck mean for pharmaceutical manufacturers?

For pharmaceutical manufacturers, FDA PreCheck means a new facility can get FDA feedback on design and quality systems years before an application is reviewed, which lowers the risk of late facility deficiencies delaying approval. For everyone else, it signals where FDA is focusing: new domestic capacity for critical medicines, US sourcing and supply chain resilience. It does not change the rules for existing plants.

FDA PreCheck benefits and limits

The FDA PreCheck benefits described by the agency are earlier technical guidance, less repeated review of the same facility information across applications, and earlier, better-informed inspection decisions. FDA's selection announcement says the pilot can identify potential facility issues before they become deficiencies that delay or prevent approval. The limits are just as important. Participation does not guarantee a faster review, an approval or a favorable inspection, and it does not relieve the company of any current good manufacturing practice obligation. A positive design review is not a release of product, and a site visit is not an inspection.

How a facility team can prepare

Whether or not a company is in the first cohort, the pilot's structure is a useful checklist for a new site. A practical sequence looks like this:

1. Map facility milestones (design, construction, installation and qualification, pre-production) against the application plan so regulatory questions are raised while changes are still affordable.

2. Document facility and quality system information in a form that can be referenced across several applications, rather than rewriting it for each filing.

3. Decide early whether an active ingredient will be covered by a Type II DMF and when it should be reviewed.

4. Track domestic sourcing commitments for active ingredients and key starting materials, since FDA treated them as a selection priority.

5. Monitor FDA's program and submission pages for any announcement of a later cohort or wider scope.

What it means for the supply chain around a new plant

A new domestic plant changes logistics patterns well before commercial launch. Qualification and engineering batches, reference standards, test samples, and equipment parts move between the site, contract laboratories and suppliers, often on tight schedules. Some starting materials and specialized components will still be imported, so customs and regulatory documentation for inbound shipments stays in the plan even as finished-product sourcing moves onshore. Mercury's guide to how pharma tariffs are reshaping life science shipping covers the trade side of that shift.

Once the site is approved and producing, the quality organization sets release conditions and the distribution network has to execute them. That includes storage under the right conditions, temperature-controlled transport for products that require it, and serialization and tracing obligations. Mercury's first-mile pharma logistics steps explain the handoff from manufacturer to first carrier, the guide to GMP warehousing covers storage, and the DSCSA requirements for pharmaceutical shippers cover traceability.

For a new site, it helps to keep regulatory readiness and shipment readiness on separate but linked plans. A productive FDA meeting does not mean a batch can ship. Receiving sites, packaging qualification, pickup windows and records for each product type should be confirmed before the first commercial movement, and a missed collection or temperature deviation should have a documented response while trained staff and storage space are available. Mercury supports manufacturers with temperature-controlled shipping and clinical and commercial drug logistics as new capacity comes online.